ReviewVirulence2022
The impact of infection with COVID-19 on the respiratory microbiome: A narrative review.
Review in Virulence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- SARS‑CoV‑2 Associated Shifts in the Upper Respiratory Tract Mycobiome in Non-hospitalized Cases.Mycopathologia · 2026Article
- Assessment of the bacterial community of the human upper respiratory tract in patients affected by Covid-19.Genetics and molecular biology · 2026Article
- The intersection between human metapneumovirus and the respiratory microbiome.Virology journal · 2025Review
- Pathogenic and periodontal bacteria may contribute to the fatal outcome of critically ill elderly COVID-19 patients.Scientific reports · 2025Article
- Human microbiome in post-acute COVID-19 syndrome (PACS).Current research in microbial sciences · 2025Article
- Major alteration of lung microbiome and the host responses in critically ill COVID-19 patients with high viral load.Scientific reports · 2024Article
- Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair.International journal of molecular sciences · 2024Review
- Major alteration of Lung Microbiome and the Host Reaction in critically ill COVID-19 Patients with high viral load.Research square · 2024Article
- A multi-omics strategy to understand PASC through the RECOVER cohorts: a paradigm for a systems biology approach to the study of chronic conditions.Frontiers in systems biology · 2024Review
- Dynamics of the Microbiota and Its Relationship with Post-COVID-19 Syndrome.International journal of molecular sciences · 2023Review
- Metatranscriptome Analysis of Nasopharyngeal Swabs across the Varying Severity of COVID-19 Disease Demonstrated Unprecedented Species Diversity.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has affected millions of individuals with various implications. Consistent with the crucial role of the microbiome in determining health and disease in humans, various studies have investigated the gut and respiratory microbiome effect on the COVID-19. Microbiota dysbiosis might support the entry, replication, and establishment of SARS-CoV-2 infection by modulating various mechanisms. One of the main mechanisms that the modulation of respiratory microbiota composition during the COVID-19 infection affects the magnitude of the disease is changes in innate and acquired immune responses, including inflammatory markers and cytokines and B- and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.